Managing fistula in advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a standardized approach to treat a new fistula (an abnormal opening between the esophagus and windpipe or chest) in people with advanced esophageal squamous cell cancer. It aims to improve management and outcomes for this difficult complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of esophageal squamous cell cancer that cannot be removed by surgery.
- You have a newly diagnosed fistula in the esophagus (an abnormal connection to the windpipe or chest).
- You have had no more than 3 previous types of cancer treatment (like chemotherapy).
- You are well enough to be up and about (ECOG score 0-2) and have adequate organ function (like blood counts, liver, kidneys).
- You do not have other serious medical conditions (like severe heart disease, active infections, or another cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests whether a personalized treatment plan, chosen using a lab-grown model of your tumor, works better than standard therapy for esophageal cancer that can be surgically removed. It aims to find the most effective drugs for you before surgery.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.